Sangamo Therapeutics Announces Pfizer's Phase 3 Trial Of Giroctocogene Fitelparvovec Meets Primary And Key Secondary Objectives; Eligible For Up To $220M In Milestone Payments And 14%-20% Royalties If Approved And Commercialized
Sangamo Therapeutics Announces Pfizer's Phase 3 Trial Of Giroctocogene Fitelparvovec Meets Primary And Key Secondary Objectives; Eligible For Up To $220M In Milestone Payments And 14%-20% Royalties If Approved And Commercialized
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.